cd276/b7-h3

Anti-Mouse CD276/B7-H3 Antibody (MJ18) is an IgG1, κ antibody inhibitor derived from rats, targeting mouse CD276/B7-H3.

Mirzotamab is an IgG1κ antibody targeting CD276/B7-H3 and is the naked antibody to Mirzotamab clezutoclax, consisting of 1320 amino acids.

Vobramitamab (AEX-4089) is a humanized monoclonal antibody (mAb) targeting the B7-H3 antigen (CD276) which is conjugated to the prodrug seco-duocarmycin hydroxybenzamide azaindole (seco-DUBA) through a enzymatically cleavable peptide-based linker, thereby creating the investigational antibody-drug conjugate (ADC) known as MGC018.

Anti-B7-H3/CD276 Antibody is a human-derived antibody produced from CHO cells, targeting B7-H3/CD276. It features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Tambotatug is a humanized IgG1κ monoclonal antibody inhibitor that targets CD276/B7-H3, demonstrating anti-tumor activity. It is applicable in cancer immunotherapy, including studies related to colorectal cancer (CRC).